Labcorp Holdings Inc.
Rank #329Capital ReturnLH · NYSE · Healthcare
Labcorp Holdings Inc. (LH) — Rank #329 by gross profitability (GP/assets 0.22) · ROE 10.2% · Piotroski F-Score 8 / 9.
As-of 2026-09-15 · CIK 0000920148 · all metrics point-in-time as of the filing date.
About
Labcorp Holdings Inc. provides laboratory services.
Show moreShow less
It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer.
The company was founded in 1995 and is headquartered in Burlington, North Carolina.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- labcorp.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-24 | 2024-12-31filed 2025-02-25 | 2023-12-31filed 2024-02-26 | 2022-12-31filed 2023-02-28 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 681.1 | 643.5 | 577.3 | 633.9 |
| Stock-based compensation | 125.8 | 116.7 | 128.7 | 144.1 |
| Change in receivables | 125.5 | 52.3 | 103.8 | (15.9) |
| Change in inventory | 30.2 | 12.6 | 0.7 | 45.5 |
| Change in payables | (52.8) | 72.1 | (42.4) | 307.1 |
| Operating cash flow | 1,640.5 | 1,585.8 | 1,327.7 | 1,955.9 |
| Investing | ||||
| Capital expenditures | 434.5 | 489.9 | 453.6 | 481.9 |
| Acquisitions, net of cash | 582.0 | 839.0 | 671.5 | 1,164.0 |
| Investing cash flow | (1,194.0) | (1,366.8) | (1,171.5) | (1,652.2) |
| Financing | ||||
| Debt issued | — | — | — | 0.0 |
| Share repurchases | 450.0 | 250.1 | 1,000.0 | 1,100.0 |
| Dividends paid | 240.7 | 243.1 | — | — |
| Financing cash flow | (1,457.0) | 779.9 | (59.3) | (1,322.2) |
| Summary | ||||
| Free cash flow | 1,206.0 | 1,095.9 | 874.1 | 1,474.0 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?